{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:17:48Z","timestamp":1785889068313,"version":"3.56.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT22LAB120"],"award-info":[{"award-number":["DUT22LAB120"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["DUT22YG207"],"award-info":[{"award-number":["DUT22YG207"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270751"],"award-info":[{"award-number":["82270751"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20263"],"award-info":[{"award-number":["U20A20263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography A"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.chroma.2024.464701","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T10:56:40Z","timestamp":1706785000000},"page":"464701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Chimeric AQP4-based immunosorbent for highly-specific removal of AQP4-IgG from blood"],"prefix":"10.1016","volume":"1717","author":[{"given":"Xiaofei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2662-2812","authenticated-orcid":false,"given":"Fangling","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chroma.2024.464701_bib0001","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.chroma.2024.464701_bib0002","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0003","article-title":"Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: a survival meta-analysis of randomized controlled trials","volume":"2","author":"Xu","year":"2022","journal-title":"Adv. Ophthalmol. Pract. Res."},{"key":"10.1016\/j.chroma.2024.464701_bib0004","article-title":"Differences in clinical features between optic neuritis in neuromyelitis optica spectrum disorders and in multiple sclerosis","volume":"4","author":"Srikajon","year":"2018","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.chroma.2024.464701_bib0005","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-019-1594-1","article-title":"The history of neuromyelitis optica. Part 2: 'Spinal amaurosis', or how it all began","volume":"16","author":"Jarius","year":"2019","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.chroma.2024.464701_bib0006","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.chroma.2024.464701_bib0007","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.chroma.2024.464701_bib0008","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.chroma.2024.464701_bib0009","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1212\/NXI.0000000000000231","article-title":"Clinical utility of testing AQP4-IgG in CSF: guidance for physicians","volume":"3","author":"Majed","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.chroma.2024.464701_bib0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s41232-023-00291-5","article-title":"Autoimmune-mediated astrocytopathy","volume":"43","author":"Kinoshita","year":"2023","journal-title":"Inflamm. Regen."},{"key":"10.1016\/j.chroma.2024.464701_bib0011","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1093\/brain\/awab102","article-title":"Staging of astrocytopathy and complement activation in neuromyelitis optica spectrum disorders","volume":"144","author":"Takai","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.chroma.2024.464701_bib0012","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.chroma.2024.464701_bib0013","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.chroma.2024.464701_bib0014","first-page":"4025","article-title":"Astrocyte-microglia interaction drives evolving neuromyelitis optica lesion","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.chroma.2024.464701_bib0015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s40120-021-00253-4","article-title":"Neuromyelitis optica spectrum disorder: clinical burden and cost of relapses and disease-related care in US clinical practice","volume":"10","author":"Royston","year":"2021","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.chroma.2024.464701_bib0016","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0017","article-title":"Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: attack therapy and long-term management","author":"Kumpfel","year":"2023","journal-title":"J. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0018","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1177\/1352458518776584","article-title":"Treating neuromyelitis optica with azathioprine: 20-year clinical practice","volume":"25","author":"Bichuetti","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.chroma.2024.464701_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1047992","article-title":"Successful treatment of rituximab-unresponsive elderly-onset neuromyelitis optica spectrum disorder and hypogammaglobulinemia with ofatumumab plus intravenous immunoglobulin therapy in a patient with mutant FCGR3A genotype: a case report","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chroma.2024.464701_bib0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr. Treat. Options Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0021","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.chroma.2024.464701_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.msard.2019.05.011","article-title":"Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"33","author":"Espiritu","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.chroma.2024.464701_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11940-021-00667-3","article-title":"New therapeutic landscape in neuromyelitis optica","volume":"23","author":"Tugizova","year":"2021","journal-title":"Curr. Treat. Options. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0024","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.chroma.2024.464701_bib0026","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.chroma.2024.464701_bib0027","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S1092852920001625","article-title":"Response to: eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder","volume":"26","author":"Pittock","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.chroma.2024.464701_bib0028","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0029","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/2211-5056.355617","article-title":"What's new in neuromyelitis optica spectrum disorder treatment?","volume":"12","author":"Chu","year":"2022","journal-title":"Taiwan J. Ophthalmol."},{"key":"10.1016\/j.chroma.2024.464701_bib0030","first-page":"309","article-title":"[Treatment and new evidences in neuromyelitis optica spectrum disorder]","volume":"74","author":"Illes","year":"2021","journal-title":"Ideggyogy. Szle."},{"key":"10.1016\/j.chroma.2024.464701_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.652759","article-title":"Monoclonal antibody therapy in neuromyelitis optica spectrum disorders: a meta-analysis of randomized control trials","volume":"12","author":"Kong","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.chroma.2024.464701_bib0032","article-title":"Safety and efficacy of plasma exchange treatment in children with AQP4-IgG positive neuromyelitis optica spectrum disorder","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chroma.2024.464701_bib0033","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the american society for apheresis: the eighth special issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.chroma.2024.464701_bib0034","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/jca.21953","article-title":"Immunoadsorption and plasma exchange-efficient treatment options for neurological autoimmune diseases","volume":"37","author":"Boedecker","year":"2022","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.chroma.2024.464701_bib0035","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008551","article-title":"Prognostic indicators of improvement with therapeutic plasma exchange in pediatric demyelination","volume":"93","author":"Savransky","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.chroma.2024.464701_bib0036","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic plasma exchange in myasthenia gravis: a systematic literature review and meta-analysis of comparative evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0037","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jca.21324","article-title":"Immunoadsorption therapy for neuromyelitis optica spectrum disorders long after the acute phase","volume":"30","author":"Kobayashi","year":"2015","journal-title":"J. Clin. Apher."},{"key":"10.1016\/j.chroma.2024.464701_bib0038","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000529463","article-title":"Principles of therapeutic apheresis in neurological disease","volume":"50","author":"Strasser","year":"2023","journal-title":"Transfus. Med. Hemotherapy"},{"key":"10.1016\/j.chroma.2024.464701_bib0039","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3389\/fneur.2020.00778","article-title":"Pain in NMOSD and MOGAD: a systematic literature review of pathophysiology, symptoms, and current treatment strategies","volume":"11","author":"Asseyer","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0040","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221150314","article-title":"Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder","volume":"16","author":"Heigl","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.chroma.2024.464701_bib0041","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/1744-9987.12820","article-title":"Removal characteristics of immunoadsorption with the tryptophan-immobilized column using conventional and selective plasma separators in the treatment of myasthenia gravis","volume":"23","author":"Ohkubo","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"10.1016\/j.chroma.2024.464701_bib0042","unstructured":"Czarnecka M., Sok-Grochowska A., Lopko M., Otys K., Bkowski T. Aptamer-enabled adsorber device for specific removal of anti-aquaporin-4 antibodies. (2020)."},{"key":"10.1016\/j.chroma.2024.464701_bib0043","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.actbio.2020.02.028","article-title":"Nanobody-based high-performance immunosorbent for selective beta 2-microglobulin purification from blood","volume":"107","author":"Huang","year":"2020","journal-title":"Acta Biomater."},{"key":"10.1016\/j.chroma.2024.464701_bib0044","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ilar.46.3.258","article-title":"Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources","volume":"46","author":"Lipman","year":"2005","journal-title":"ILAR J."},{"key":"10.1016\/j.chroma.2024.464701_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2021.462478","article-title":"Nanobody-loaded immunosorbent for highly-specific removal of interleukin-17A from blood","volume":"1654","author":"Yao","year":"2021","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461227","article-title":"Characterization and comparison of two peptide-tag specific nanobodies for immunoaffinity chromatography","volume":"1624","author":"Ren","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0047","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.720","article-title":"Choosing an effective protein bioconjugation strategy","volume":"7","author":"Stephanopoulos","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.chroma.2024.464701_bib0048","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2023.120644","article-title":"Hydrophobic modified agar: structural characterization and application in encapsulation and release of curcumin","volume":"308","author":"Zhang","year":"2023","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.chroma.2024.464701_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/md21050299","article-title":"Extraction, modification and biomedical application of agarose hydrogels: a review","volume":"21","author":"Jiang","year":"2023","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.chroma.2024.464701_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2020.461319","article-title":"Modeling hindered diffusion of antibodies in agarose beads considering pore size reduction due to adsorption","volume":"1626","author":"Hagemann","year":"2020","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0051","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.chroma.2005.07.050","article-title":"Comparison of protein A affinity sorbents II. Mass transfer properties","volume":"1093","author":"Hahn","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0052","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1021\/acs.bioconjchem.2c00143","article-title":"SnoopLigase enables highly efficient generation of C-C-linked bispecific nanobodies targeting TNF-alpha and IL-17A","volume":"33","author":"Chen","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.chroma.2024.464701_bib0053","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s10529-019-02771-6","article-title":"The Immobilization of Candida antarctica lipase B by ZIF-8 encapsulation and macroporous resin adsorption: preparation and characterizations","volume":"42","author":"Cai","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"10.1016\/j.chroma.2024.464701_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.chroma.2019.460474","article-title":"A new tetrapeptide biomimetic chromatographic resin for antibody separation with high adsorption capacity and selectivity","volume":"1604","author":"Fang","year":"2019","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0055","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/elsc.202000097","article-title":"Increasing immunoglobulin G adsorption in dextran-grafted protein A gels","volume":"21","author":"Huan","year":"2021","journal-title":"Eng. Life Sci."},{"key":"10.1016\/j.chroma.2024.464701_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.colsurfb.2011.09.033","article-title":"Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications","volume":"90","author":"Iafisco","year":"2012","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.chroma.2024.464701_bib0057","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0021-9673(02)01901-5","article-title":"Interaction of immunoglobulin G with N,N,N',N'-ethylenediaminetetramethylenephosphonic acid-modified zirconia","volume":"989","author":"Subramanian","year":"2003","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.chroma.2024.464701_bib0058","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jchromb.2005.04.002","article-title":"Modeling of immunoglobulin uptake by N,N,N',N'-ethylenediaminetetramethylenephosphonic acid-modified zirconia particles under static and dynamic conditions","volume":"821","author":"Sarkar","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.chroma.2024.464701_bib0059","doi-asserted-by":"crossref","first-page":"02D301","DOI":"10.1116\/1.4978435","article-title":"Orientation and characterization of immobilized antibodies for improved immunoassays (review)","volume":"12","author":"Welch","year":"2017","journal-title":"Biointerphases"},{"key":"10.1016\/j.chroma.2024.464701_bib0060","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1021\/ac0015366","article-title":"Electrokinetically driven microfluidic chips with surface-modified chambers for heterogeneous immunoassays","volume":"73","author":"Dodge","year":"2001","journal-title":"Anal. Chem."},{"key":"10.1016\/j.chroma.2024.464701_bib0061","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1039\/b411179f","article-title":"Protein adsorption in static microsystems: effect of the surface to volume ratio","volume":"5","author":"Lionello","year":"2005","journal-title":"Lab Chip"},{"key":"10.1016\/j.chroma.2024.464701_bib0062","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ab.2003.10.031","article-title":"Characterization and analysis of thermal denaturation of antibodies by size exclusion high-performance liquid chromatography with quadruple detection","volume":"325","author":"Hartmann","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.chroma.2024.464701_bib0063","article-title":"One-step Preparation of a VHH-based Immunoadsorbent for the Extracorporeal Removal of beta2-microglobulin","volume":"24","author":"Zhang","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.chroma.2024.464701_bib0064","doi-asserted-by":"crossref","first-page":"7925","DOI":"10.1038\/s41598-020-64744-4","article-title":"Therapeutic apheresis within immune-mediated neurological disorders: dosing and its effectiveness","volume":"10","author":"Klingele","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.chroma.2024.464701_bib0065","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13317-019-0115-7","article-title":"Study group on autoimmune diseases of the italian society of clinical P, et al. A new M23-based ELISA assay for anti-aquaporin 4 autoantibodies: diagnostic accuracy and clinical correlation","volume":"10","author":"Tampoia","year":"2019","journal-title":"Autoimmun. Highlights"},{"key":"10.1016\/j.chroma.2024.464701_bib0066","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12883-021-02171-2","article-title":"Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD","volume":"21","author":"Hsu","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0067","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21111577","article-title":"Agarose and its derivatives as supports for enzyme immobilization","volume":"21","author":"Zucca","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.chroma.2024.464701_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2022.153612","article-title":"Why reuse spent adsorbents? The latest challenges and limitations","volume":"822","author":"Gkika","year":"2022","journal-title":"Sci. Total. Environ."},{"key":"10.1016\/j.chroma.2024.464701_bib0069","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4103\/ijn.IJN_373_19","article-title":"Immunoadsorption column reuse","volume":"31","author":"Tiwari","year":"2021","journal-title":"Indian J. Nephrol."},{"key":"10.1016\/j.chroma.2024.464701_bib0070","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1097\/TP.0000000000000457","article-title":"The reuse of immunoadsorption columns in ABO-incompatible kidney transplantation is efficient: the swiss experience","volume":"99","author":"Schiesser","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.chroma.2024.464701_bib0071","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1021\/bp00015a001","article-title":"Immunoadsorption: strategies for antigen elution and production of reusable adsorbents","volume":"8","author":"Yarmush","year":"1992","journal-title":"Biotechnol. Prog."},{"key":"10.1016\/j.chroma.2024.464701_bib0072","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4103\/0971-4065.202832","article-title":"Reusing immunoadsorption column - making the ABO incompatible renal transplant affordable","volume":"27","author":"Jha","year":"2017","journal-title":"Indian J. Nephrol."},{"key":"10.1016\/j.chroma.2024.464701_bib0073","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1749-6632.2009.04871.x","article-title":"Effector functions of antiaquaporin-4 autoantibodies in neuromyelitis optica","volume":"1173","author":"Cayrol","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.chroma.2024.464701_bib0074","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0075","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/ana.24630","article-title":"In vivo imaging reveals rapid astrocyte depletion and axon damage in a model of neuromyelitis optica-related pathology","volume":"79","author":"Herwerth","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0076","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12974-022-02420-2","article-title":"Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study","volume":"19","author":"Demuth","year":"2022","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.chroma.2024.464701_bib0077","article-title":"Dynamic changes in AQP4-IgG level and immunological markers during protein-a immunoadsorption therapy for NMOSD: a case report and literature review","volume":"12","author":"Chen","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.chroma.2024.464701_bib0078","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3988\/jcn.2013.9.1.36","article-title":"Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels","volume":"9","author":"Kim","year":"2013","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.chroma.2024.464701_bib0079","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2012.07.008","article-title":"Astrocytic autoantibody of neuromyelitis optica (NMO-IgG) binds to aquaporin-4 extracellular loops, monomers, tetramers and high order arrays","volume":"40","author":"Iorio","year":"2013","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.chroma.2024.464701_bib0080","doi-asserted-by":"crossref","first-page":"16516","DOI":"10.1074\/jbc.M111.227298","article-title":"Binding affinity and specificity of neuromyelitis optica autoantibodies to aquaporin-4 M1\/M23 isoforms and orthogonal arrays","volume":"286","author":"Crane","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.chroma.2024.464701_bib0081","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.chroma.2024.464701_bib0082","first-page":"4405","article-title":"Super-resolution imaging of aquaporin-4 orthogonal arrays of particles in cell membranes","volume":"125","author":"Rossi","year":"2012","journal-title":"J. Cell Sci."}],"container-title":["Journal of Chromatography A"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324000748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021967324000748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T06:28:15Z","timestamp":1758263295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021967324000748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":82,"alternative-id":["S0021967324000748"],"URL":"https:\/\/doi.org\/10.1016\/j.chroma.2024.464701","relation":{},"ISSN":["0021-9673"],"issn-type":[{"value":"0021-9673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric AQP4-based immunosorbent for highly-specific removal of AQP4-IgG from blood","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography A","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chroma.2024.464701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"464701"}}